IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IRADIMED CORP on June 16, 2020, regarding events occurring on May 28, 2020. The filing details the separation of Leslie McDonnell, the Company's President and Chief Executive Officer, and her resignation from the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the severance package for the departing CEO:
- Severance Cash Payment: $400,000 gross (equivalent to 12 months of base salary), subject to withholdings and revocation provisions.
- Health Benefits: A taxable lump sum covering 12 months of employer insurance premiums plus an amount to cover estimated federal and state income taxes on that payment.
- Equity Acceleration: All unvested restricted stock units and unvested/unexercised stock options were accelerated and deemed vested as of May 28, 2020.
Material Changes
The primary material change is the immediate departure of the CEO and a director effective May 28, 2020. This follows a previous 8-K filing on May 29, 2020, which first announced the separation. The June 16 filing formalizes the terms of the Confidential Separation Agreement and General Release.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the execution of the separation agreement. The agreement includes standard restrictive covenants and a general release binding on both parties. Severance benefits are conditioned upon Ms. McDonnell's execution and non-revocation of the agreement.
Investor Verification Checklist
- Verify the appointment of an interim or permanent CEO to replace Leslie McDonnell.
- Review the full text of the Confidential Separation Agreement (Exhibit 10.1) for specific revocation clauses and restrictive covenants.
- Assess the impact of the equity acceleration on the company's share count and dilution.
- Confirm the Company's operational continuity plans following the leadership transition.